HIV

The AJMC® HIV compendium is a comprehensive resource for clinical news and expert insights for the condition, including disparities in care, prevention of infection among at-risk groups, and the importance of viral suppression.

Latest News

HIV | Image credit: Corona Borealis - stock.adobe.com
New Data Provide Clearer Picture on Adherence to Lenacapavir

November 18th 2024

An update from the PURPOSE 2 trial focused on adherence and pharmacokinetics data for lenacapavir, used to prevent HIV.

HIV | Image credit: RAJCREATIONZS - stock.adobe.com
BIC/FTC/TAF Effective at Virologic Suppression in HIV Presenting Late

November 15th 2024

Liver | Image credit: PIC4U - stock.adobe.com
Liver Steatosis, Fibrosis Highly Prevalent in People Living With HIV

November 12th 2024

Madalitso Juwayeyi
Empowering Young Women in the Fight Against HIV

November 8th 2024

HIV/AIDS | Image credit: SpeedShutter - stock.adobe.com
Controlling Spread of Drug-Resistant HIV May Necessitate Interventions

November 4th 2024

Clarifying USPSTF Recommendations for HIV Pre-Exposure Prophylaxis (PrEP)

This discussion focuses on how to address barriers and disparities as obstacles to using PrEP, with a focus on USPSTF PrEP guidelines and ACA Part 47 for payers and providers.

This multi-stakeholder roundtable panel discussion will focus on how to address barriers and disparities as obstacles to the use of PrEP, with a focus on increased understanding and education around US Preventive Services Task Force (USPSTF) PrEP guidelines and Affordable Care Act Part 47 for payers and providers.
Continuing Medical Education
View All
November 21st 2024

Navigating the HIV Treatment Frontier: Equipping Managed Care Professionals With Strategies for Innovation, Access, and Adherence

1.5 Credits / HIV/AIDS, Infectious Diseases

More News

doctor holding tablet, graphic of medical symbols
March 9th 2023

Study Finds Moderate to Good Performance in Externally Validated HIV Risk Models

Hayden E. Klein
Researchers found that only 8 of 18 HIV risk assessment models have been externally validated and show moderate-to-good discrimination ability for HIV infection prediction.
MDR HIV Treatment Approaches and Considerations for Therapeutic Adjustments
March 8th 2023

MDR HIV Treatment Approaches and Considerations for Therapeutic Adjustments

Therapy adjustments in MDR HIV are explored by Dr Sension.
Pharmacotherapeutic Treatment Options for Treating MDR HIV
March 8th 2023

Pharmacotherapeutic Treatment Options for Treating MDR HIV

Optimized background regimens are highlighted in the treatment approach for MDR HIV by Michael Sension, MD.
man holding pill bottle
March 4th 2023

High Resilience Linked to High PrEP Use Among Canadian MSM

Hayden E. Klein
The study also showed, despite an existing association between discrimination based on sexual orientation and HIV pre-exposure prophylaxis (PrEP) use, increased resilience reduced the effects of such discrimination on PrEP use.
pharmacy sign on building
March 2nd 2023

Walgreens, Doordash, Uber Partner to Improve HIV Medication Access

Hayden E. Klein
The 3 companies announced a partnership to provide free, same-day prescription delivery of HIV pre-exposure prophylaxis (PrEP) and antiretroviral medications.
Social Determinants of Health Impacting Patients Diagnosed with MDR HIV
March 2nd 2023

Social Determinants of Health Impacting Patients Diagnosed with MDR HIV

Dr Haumschild leads a discussion highlighting goals of therapy and social determinants of health affecting MDR HIV diagnosis and treatment.
Economic and Social Burdens Associated with MDR HIV
March 2nd 2023

Economic and Social Burdens Associated with MDR HIV

A panel of experts explore burdens impacting patients diagnosed with MDR HIV.
globe with red HIV ribbon on it
February 24th 2023

Global Case Series Characterizes Severe Form of Mpox in People With Advanced HIV

Hayden E. Klein
A global case series described a severe form of mpox linked to a 15% mortality rate among people living with HIV and low CD4 counts.
Resistance Mechanisms Leading to MDR HIV
February 23rd 2023

Resistance Mechanisms Leading to MDR HIV

Michael Sension, MD, provides insights on resistance mechanisms promoting MDR HIV.
Incidence and Prevalence of MDR HIV
February 23rd 2023

Incidence and Prevalence of MDR HIV

Ryan Haumschild, PharmD, MS, MBA, opens a panel discussion surrounding the incidence and prevalence of multidrug-resistant (MDR) HIV.
coffee and newspaper
February 21st 2023

What We’re Reading: Fifth Person Cured of HIV; New Possible Future Stroke Treatment; Pushback on Proposed FDA Healthy Food Guidelines

AJMC Staff
A fifth person has been cured of HIV following a stem cell transplant for cancer; a new study examining a treatment of spinal cord stimulation after stroke had favorable results; some food companies enraged by proposed FDA healthy food guidelines.
globe with red HIV ribbon on it
February 17th 2023

HIV Screening, PrEP Program in Zambia May Serve as Model for Prisons Worldwide

Hayden E. Klein
An HIV prevention and treatment program implemented in Zambian criminal justice facilities demonstrated high levels of pre-exposure prophylaxis (PrEP) uptake among at-risk individuals.
HIV test
February 10th 2023

CDC Report Highlights 2021 Trends in HIV Testing, Treatment, Risk Behaviors Among MSM

Hayden E. Klein
Interviews with 2241 men who have sex with men (MSM) without HIV showed high levels of HIV testing, but lower levels of preventative treatment in 2021.
coffee and newspaper
February 8th 2023

What We’re Reading: Biden’s SOTU Underscores Health Progress, Plans; DC Sees Rising HIV Diagnoses; The Pill Club to Pay $18.3M in Medicaid Fraud

AJMC Staff
Biden’s State of the Union (SOTU) address emphasized drug access for those on Medicare, the Cancer Moonshot, and more; HIV diagnoses are increasing in Washington, DC, from missed wellness visits and preventive visits upended during the start of COVID-19; California online women’s pharmacy The Pill Club will pay $18.3 million in Medicaid fraud settlement with California.
What We’re Reading: J&J Ends HIV Vaccine Trial; Deaths After Abortion Bans; Sanofi Looks to Hemophilia A Drug
January 19th 2023

What We’re Reading: J&J Ends HIV Vaccine Trial; Deaths After Abortion Bans; Sanofi Looks to Hemophilia A Drug

AJMC Staff
Johnson & Johnson (J&J) ends late-stage HIV vaccine trial; mothers in states with abortion bans are almost 3 times more likely to die before, during, and after birth; Sanofi hopes to release a drug for hemophilia A in 2023.
metal spoon holding vitamin D pills
January 4th 2023

Women With HIV More Likely to Get Vitamin D From Supplements, Not Diet

Hayden E. Klein
A study showed that Canadian women living with HIV were less likely to get vitamin D through dairy consumption, but more likely to take vitamin D supplements, compared with women without HIV.
the top 5 HIV content of 2022
December 28th 2022

Top 5 Most-Viewed HIV Content of 2022

Justina Petrullo
This year’s most-viewed HIV content focused on disparities in HIV care, an emerging nonepidemic Kaposi sarcoma subtype, and the need for more research on hepatitis B endurance.
New York City skyline panorama at sunrise
December 22nd 2022

HIV Self-testing Relatively Uncommon Among MSM in Urban Areas

Hayden E. Klein
Of 6563 men who have sex with men (MSM) living in urban areas in 2017, only 7.7% reported HIV self-testing in the past year.
HIV PrEP pill in hand
December 17th 2022

USPSTF Recommends HIV PrEP

Hayden E. Klein
The US Preventive Services Task Force (USPSTF) announced its recommendation for HIV pre-exposure prophylaxis (PrEP).
doctor talking to patient with clipboard on desk
December 15th 2022

Conversations Around HIV PrEP With Adolescents Vary Between Urban, Rural Family Physicians

Hayden E. Klein
This new study shows that family medicine physicians in rural areas tend to be less comfortable in HIV pre-exposure prophylaxis (PrEP)-related clinical activities and conversations with adolescents than those in urban areas.
hundred dollar bills covered by pills
December 7th 2022

ICYMI: Top Highlights From AMCP Nexus 2022

AJMC Staff
Perry N. Halkitis, PhD, MS, MPH
December 1st 2022

Contributor: On World AIDS Day—Lessons Drawn From HIV, Monkeypox, and COVID-19

Perry N. Halkitis, PhD, MS, MPH
Dr Halkitis is currently working on his new book "People, Politics, & Public Health: How the American People Created the HIV, COVID-19, and Other Modern-Day Pandemics," to be published by Johns Hopkins University Press.
HIV Care Should Be Comprehensive, Says Dr Jana Dickter
November 29th 2022

HIV Care Should Be Comprehensive, Says Dr Jana Dickter

Hayden E. Klein Skylar Jeremias
Jana K. Dickter, MD, associate clinical professor, Division of Infectious Diseases, City of Hope, addresses what health systems need to do to improve HIV therapy accessibility and affordability.
graphic of people
November 26th 2022

Social Vulnerability Thought to Impact Diagnosis of HIV and Receival of Care

Justina Petrullo
Communities that are experiencing the most social vulnerability may need stronger preventative measures against HIV and increased levels of HIV care.
Kevin N. Astle, PharmD
November 26th 2022

Dr Kevin Astle: Long-Acting Injectables Are a Game Changer for Adherence

Hayden E. Klein
Now that long-acting injectables are approved, the next big concern is patient access, said Kevin N. Astle, PharmD, BCPS, BCACP, AAHIVP, CDES, assistant professor at the University of South Florida Taneja College of Pharmacy.
Triple Therapy Maintains HIV Viral Suppression in Patients With Mutation, Prior Virologic Failure
November 25th 2022

Triple Therapy Maintains HIV Viral Suppression in Patients With Mutation, Prior Virologic Failure

Hayden E. Klein
According to the study authors, bictegravir, emtricitabine, and tenofovir alafenamide (BIC/FTC/TAF) may be an option for simplification following viral suppression.
Long-Acting Injectables Promote PrEP Access, Adherence, Says Dr Tam Phan
November 22nd 2022

Long-Acting Injectables Promote PrEP Access, Adherence, Says Dr Tam Phan

Hayden E. Klein
Tam C. Phan, PharmD, AAHIVP, assistant professor of clinical pharmacy, USC School of Pharmacy, talks about how HIV pre-exposure prophylaxis (PrEP) therapies in the pipeline address disparities in patient access and adherence.
Jana Dickter, MD
November 16th 2022

Stem Cell Transplant May Be Viable Treatment for Patients With HIV, Leukemia, Says Dr Jana Dickter

Hayden E. Klein Skylar Jeremias
Jana K. Dickter, MD, associate clinical professor, Division of Infectious Diseases, City of Hope, discusses a patient's experience being the oldest person to successfully undergo a stem cell transplant while living with HIV and leukemia.
group of people wearing white t shirts and red HIV ribbons
November 3rd 2022

Earlier ART Linked to Better Long-term HIV Outcomes

Hayden E. Klein
An extended follow-up to a 2015 study further supports that beginning antiretroviral therapy (ART) earlier is linked to better long-term outcomes compared with delayed ART initiation.
What We're Reading
October 27th 2022

What We’re Reading: State Determines Health Outcomes; Increasing Comorbid HIV/Monkeypox Infection; More Children Uninsured

AJMC Staff
A recent study found that Americans die younger in states with conservative policies; most patients admitted to the hospital with monkeypox also have HIV; 4 million children are uninsured due to state policies, according to new research.
<12345678910
...
30>

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

© 2024 MJH Life Sciences® and AJMC®.
All rights reserved.

About
Contact
Editorial Boards
Advertise
Do Not Sell My Information
Terms & Conditions
Privacy Policy
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo